Adamas Pharmaceuticals, Inc. (ADMS): Price and Financial Metrics


Adamas Pharmaceuticals, Inc. (ADMS): $5.18

0.30 (+6.15%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ADMS POWR Grades


  • Growth is the dimension where ADMS ranks best; there it ranks ahead of 73.2% of US stocks.
  • The strongest trend for ADMS is in Momentum, which has been heading down over the past 48 weeks.
  • ADMS ranks lowest in Momentum; there it ranks in the 5th percentile.

ADMS Stock Summary

  • Adamas Pharmaceuticals Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than just 0.8% of US listed stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at -6.93 for Adamas Pharmaceuticals Inc; that's greater than it is for just 2.19% of US stocks.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for ADMS comes in at -30.61% -- higher than that of only 9.19% of stocks in our set.
  • Stocks that are quantitatively similar to ADMS, based on their financial statements, market capitalization, and price volatility, are TXMD, UIS, MSON, ESI, and KIDS.
  • ADMS's SEC filings can be seen here. And to visit Adamas Pharmaceuticals Inc's official web site, go to www.adamaspharma.com.

ADMS Valuation Summary

  • In comparison to the median Healthcare stock, ADMS's price/sales ratio is 77.09% lower, now standing at 2.6.
  • ADMS's price/sales ratio has moved down 0.6 over the prior 90 months.
  • ADMS's price/sales ratio has moved down 0.6 over the prior 90 months.

Below are key valuation metrics over time for ADMS.

Stock Date P/S P/B P/E EV/EBIT
ADMS 2021-08-31 2.6 -53.3 -3.9 -6.3
ADMS 2021-08-30 2.5 -51.2 -3.7 -6.1
ADMS 2021-08-27 2.5 -50.7 -3.7 -6.1
ADMS 2021-08-26 2.6 -53.1 -3.9 -6.3
ADMS 2021-08-25 2.6 -52.8 -3.9 -6.3
ADMS 2021-08-24 2.5 -50.7 -3.7 -6.1

ADMS Growth Metrics

  • Its 2 year price growth rate is now at -88.37%.
  • Its 2 year cash and equivalents growth rate is now at -10.6%.
  • The 3 year cash and equivalents growth rate now stands at -40.11%.
Over the past 15 months, ADMS's revenue has gone up $25,016,000.

The table below shows ADMS's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 82.469 -51.421 -55.106
2021-03-31 79.291 -54.458 -53.328
2020-12-31 74.461 -50.708 -57.403
2020-09-30 69.799 -58.694 -62.205
2020-06-30 63.556 -66.5 -77.871
2020-03-31 57.453 -77.175 -92.176

ADMS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ADMS has a Quality Grade of C, ranking ahead of 61.93% of graded US stocks.
  • ADMS's asset turnover comes in at 0.576 -- ranking 63rd of 677 Pharmaceutical Products stocks.
  • RDUS, CSBR, and FOLD are the stocks whose asset turnover ratios are most correlated with ADMS.

The table below shows ADMS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.576 0.976 -0.250
2021-03-31 0.571 0.977 -0.224
2020-12-31 0.562 0.973 -0.226
2020-09-30 0.488 0.973 -0.233
2020-06-30 0.410 0.963 -0.297
2020-03-31 0.334 0.954 -0.352

ADMS Price Target

For more insight on analysts targets of ADMS, see our ADMS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $8.79 Average Broker Recommendation 1.61 (Moderate Buy)

ADMS Stock Price Chart Interactive Chart >

Price chart for ADMS

ADMS Price/Volume Stats

Current price $5.18 52-week high $9.15
Prev. close $4.88 52-week low $2.96
Day low $4.72 Volume 387,300
Day high $5.24 Avg. volume 441,161
50-day MA $4.75 Dividend yield N/A
200-day MA $5.06 Market Cap 236.19M

Adamas Pharmaceuticals, Inc. (ADMS) Company Bio


Adamas Pharmaceuticals is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company was founded in 2000 and is based in Emeryville, California.


ADMS Latest News Stream


Event/Time News Detail
Loading, please wait...

ADMS Latest Social Stream


Loading social stream, please wait...

View Full ADMS Social Stream

Latest ADMS News From Around the Web

Below are the latest news stories about Adamas Pharmaceuticals Inc that investors may wish to consider to help them evaluate ADMS as an investment opportunity.

Adamas Announces GOCOVRI Presentations at the Upcoming International Parkinson and Movement Disorder Societys (MDS) Congress

EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced five posters will be presented at the International Parkinson and Movement Disorder Society (MDS) Virtual Congress, taking place September 17 22, 2021. The poster presentations will focus on GOCOVRI® (amantadine) extended-release capsules, the first and only FD

Business Wire | September 16, 2021

Adamas Announces GOCOVRI Presentations at the Upcoming International Parkinson and Movement Disorder Society’s (MDS) Congress

EMERYVILLE, Calif., September 16, 2021--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced five posters will be presented at the International Parkinson and Movement Disorder Society (MDS) Virtual Congress, taking place September 17 – 22, 2021. The poster presentations will focus on GOCOVRI® (amantadine) extended-release capsules, the first and only

Yahoo | September 16, 2021

Adamas Announces New Employment Inducement Grants

EMERYVILLE, Calif., September 10, 2021--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted seven new employees restricted stock units to acquire 94,750 shares of the company’s common stock. The restricted stock units vest over three years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) o

Yahoo | September 10, 2021

Adamas to Present at Upcoming September Investor Conferences

EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that management will present at the following virtual investor conferences during the month of September 2021: H.C. Wainwright 23rd Annual Global Investment Conference, a pre-recorded presentation will be available beginning on Monday, September 13 at 7:00 am ET

Business Wire | August 30, 2021

Adamas Announces New Employment Inducement Grant

EMERYVILLE, Calif., August 13, 2021--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted three new employees restricted stock units to acquire 38,500 shares of the company’s common stock. The restricted stock units vest over three years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of t

Yahoo | August 13, 2021

Read More 'ADMS' Stories Here

ADMS Price Returns

1-mo 15.63%
3-mo -1.89%
6-mo 0.58%
1-year 28.22%
3-year -74.13%
5-year -68.61%
YTD 19.63%
2020 14.25%
2019 -55.62%
2018 -74.80%
2017 100.53%
2016 -40.32%

Continue Researching ADMS

Here are a few links from around the web to help you further your research on Adamas Pharmaceuticals Inc's stock as an investment opportunity:

Adamas Pharmaceuticals Inc (ADMS) Stock Price | Nasdaq
Adamas Pharmaceuticals Inc (ADMS) Stock Quote, History and News - Yahoo Finance
Adamas Pharmaceuticals Inc (ADMS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.7455 seconds.